Biopharma’s role in tackling coronavirus
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Ipsen doubles down on rare bone disease
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Upcoming events – key tests approach for Biogen and Kalvista
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Upcoming events – Pfizer and Glycomimetics await sickle cell data and Biocryst tries again
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
Idera’s reinvention takes a hit
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
The other shoe drops for Pharming
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire dodges pricing questions as lanadelumab’s big day nears
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
Logic defeats Idercryst and Baker Brothers
The much criticised takeover of Idera by Biocryst will not, after all, take place.
